HighTower Advisors LLC Sells 20,000 Shares of iRadimed Corporation $IRMD

HighTower Advisors LLC trimmed its holdings in iRadimed Corporation (NASDAQ:IRMD) by 33.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,361 shares of the medical equipment provider’s stock after selling 20,000 shares during the quarter. HighTower Advisors LLC owned about 0.32% of iRadimed worth $2,872,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of IRMD. CWM LLC grew its holdings in iRadimed by 62.2% in the third quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 211 shares during the period. State of Alaska Department of Revenue purchased a new position in shares of iRadimed during the third quarter valued at approximately $47,000. Tower Research Capital LLC TRC boosted its position in shares of iRadimed by 191.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 495 shares in the last quarter. Spire Wealth Management purchased a new stake in shares of iRadimed in the 2nd quarter worth approximately $60,000. Finally, State of Wyoming purchased a new stake in shares of iRadimed in the 3rd quarter worth approximately $72,000. 92.34% of the stock is owned by hedge funds and other institutional investors.

iRadimed Stock Performance

IRMD opened at $102.42 on Friday. The company’s 50-day simple moving average is $99.35 and its two-hundred day simple moving average is $86.20. The stock has a market capitalization of $1.30 billion, a P/E ratio of 58.53 and a beta of 1.11. iRadimed Corporation has a 52-week low of $47.48 and a 52-week high of $107.90.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.05. iRadimed had a net margin of 26.82% and a return on equity of 23.85%. The firm had revenue of $22.69 million during the quarter, compared to analysts’ expectations of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. Research analysts forecast that iRadimed Corporation will post 1.66 EPS for the current fiscal year.

iRadimed Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Monday, February 23rd will be issued a $0.20 dividend. The ex-dividend date of this dividend is Monday, February 23rd. This is an increase from iRadimed’s previous quarterly dividend of $0.17. This represents a $0.80 annualized dividend and a dividend yield of 0.8%. iRadimed’s dividend payout ratio is presently 45.71%.

Insider Buying and Selling at iRadimed

In other iRadimed news, CEO Roger E. Susi sold 5,000 shares of the business’s stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $100.65, for a total transaction of $503,250.00. Following the completion of the sale, the chief executive officer directly owned 2,262,500 shares in the company, valued at $227,720,625. The trade was a 0.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO John Glenn sold 15,000 shares of the company’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the sale, the chief financial officer directly owned 7,362 shares of the company’s stock, valued at $716,248.98. The trade was a 67.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 45,000 shares of company stock valued at $4,408,150 in the last ninety days. 36.80% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Weiss Ratings reiterated a “buy (b-)” rating on shares of iRadimed in a research note on Monday, December 29th. Zacks Research upgraded iRadimed to a “hold” rating in a report on Tuesday, November 4th. Lake Street Capital reiterated a “buy” rating and issued a $120.00 price target on shares of iRadimed in a research note on Wednesday, February 11th. Finally, Roth Mkm restated a “buy” rating and set a $120.00 price objective on shares of iRadimed in a research note on Tuesday, February 10th. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, iRadimed has an average rating of “Moderate Buy” and a consensus price target of $120.00.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.